Completed PHASE4 INTERVENTIONAL NCT00327691

A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels (TNT)

The Effect Of LDL-Cholesterol, Lowering Beyond Currently Recommended Minimum Targets On Coronary Heart Disesse (CHD) Recurrence In Patients With Pre-Existing CHD

Sponsor: Pfizer

Conditions Cardiovascular Disease Cerebrovascular Accident Coronary Heart Disease

Interventions Atorvastatin

Updated 7 times since 2017 Last updated: May 1, 2007 Started: Apr 30, 1998 Completion: Aug 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Cardiovascular Disease and Cerebrovascular Accident, this trial is completed. The trial is conducted by Pfizer and has accumulated 7 data snapshots since 1998. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE4
Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Apr 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's-Hertogenbosch, Netherlands , Aalst, Belgium , Adelaide, Australia , Agen, France , Alabaster, United States , Albany, United States , Aldershot, United Kingdom , Alkmaar, Netherlands , Allentown, United States , Amersfoort, Netherlands and 228 more locations